These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Prescription and regulation of the health system]. Le Pen C Encephale; 1994 Jun; 20 Spec No 2():285-6. PubMed ID: 8088248 [No Abstract] [Full Text] [Related]
6. Diagnosis and treatment of depression in general practice. Freeling P Br J Psychiatry Suppl; 1993 Jul; (20):14-9. PubMed ID: 8352911 [No Abstract] [Full Text] [Related]
7. Economics of treatment of depression. Thompson C Br J Psychiatry; 1995 Jul; 167(1):112. PubMed ID: 7551592 [No Abstract] [Full Text] [Related]
8. [Therapeutic drug monitoring of antidepressives--therapeutic and health economics advantages]. Grasmäder K; Lohmann PL; Kuss HJ; Laux G; Hiemke C; Rao ML Med Monatsschr Pharm; 2003 May; 26(5):162-4. PubMed ID: 12784507 [No Abstract] [Full Text] [Related]
9. Editorial. J Ment Health Policy Econ; 2015 Dec; 18(4):163-4. PubMed ID: 26785509 [No Abstract] [Full Text] [Related]
10. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. Burke MJ; Silkey B; Preskorn SH J Clin Psychiatry; 1994 Sep; 55 Suppl A():42-52; discussion 53-4, 98-100. PubMed ID: 7961542 [TBL] [Abstract][Full Text] [Related]
11. Does direct-to-consumer advertising of antidepressants lead to a net social benefit? Jureidini J; Mintzes B; Raven M Pharmacoeconomics; 2008; 26(7):557-66; discussion 567-8. PubMed ID: 18563947 [No Abstract] [Full Text] [Related]
12. [The burden of depressive disorders in Russian psychiatric services]. Gurovich IIa; Liubov EB; Chapurin SA; Churilin IuIu; Enaliev IR Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(3):77-82. PubMed ID: 20607927 [No Abstract] [Full Text] [Related]
13. Opportunity cost of antidepressant prescribing in England: analysis of routine data. Hollinghurst S; Kessler D; Peters TJ; Gunnell D BMJ; 2005 Apr; 330(7498):999-1000. PubMed ID: 15778232 [No Abstract] [Full Text] [Related]
14. Long term pharmacotherapy of depression. Can reduce relapses and recurrences in major depression. Edwards JG BMJ; 1998 Apr; 316(7139):1180-1. PubMed ID: 9552990 [No Abstract] [Full Text] [Related]
15. Establishing the real cost of depression. Sheehan DV Manag Care; 2002 Aug; 11(8 Suppl):7-10; discussion 21-5. PubMed ID: 12233202 [No Abstract] [Full Text] [Related]
16. The costs of depression. Kind P; Sorensen J Int Clin Psychopharmacol; 1993 Jan; 7(3-4):191-5. PubMed ID: 8468441 [TBL] [Abstract][Full Text] [Related]
17. Costs of psychological treatment. Moscarelli M; Rupp A J Ment Health Policy Econ; 2008 Mar; 11(1):1-2. PubMed ID: 18540131 [No Abstract] [Full Text] [Related]
18. Debits and credits in the management of depression. Henry JA Br J Psychiatry Suppl; 1993 Jul; (20):33-9. PubMed ID: 8352915 [TBL] [Abstract][Full Text] [Related]
19. The economic evaluation of antidepressant drug therapy. Br J Psychiatry Suppl; 1993 Jul; (20):5-42. PubMed ID: 8352916 [No Abstract] [Full Text] [Related]
20. Cost effectiveness of botulinum toxins for the treatment of depression: preliminary observations. Beer K J Drugs Dermatol; 2010 Jan; 9(1):27-30. PubMed ID: 20120422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]